Skip to content
PeptideInfowiki
Index by category›

Reproductive & Hormonal

Buserelin

Suprecur; Suprefact; buserelin acetate

1 min read · Updated July 27, 2026 · 3 references

Curated by PeptideInfo Wikilast reviewed how we verify

Explored forApproved peptide medicines — verification pilot
In brief · TL;DR
Approved abroad — not FDA/EMA· UK (not FDA/EMA)

A GnRH agonist authorized nationally in the United Kingdom for specialist fertility protocols; it is not FDA-approved or centrally authorized by EMA.

Evidence: Approved in some countries; not by the FDA or EMA.

Approved in: United Kingdom national authorization (Suprecur); not FDA-approved and not an EMA centralized authorization

  • A GnRH agonist authorized nationally in the United Kingdom for specialist fertility protocols; it is not FDA-approved or centrally authorized by EMA.
  • After an initial stimulatory phase, continued exposure desensitizes pituitary GnRH receptors and suppresses gonadotropin secretion.
  • Use can initially worsen hormone-driven symptoms and later cause hypoestrogenic or hypoandrogenic effects, bone loss and mood or metabolic effects. The exact protocol depends on indication and product.
↓ Read the full referenced entry below

A GnRH agonist authorized nationally in the United Kingdom for specialist fertility protocols; it is not FDA-approved or centrally authorized by EMA.

Overview

A GnRH agonist authorized nationally in the United Kingdom for specialist fertility protocols; it is not FDA-approved or centrally authorized by EMA.

Primary regulatory source

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

Identity and mechanism

After an initial stimulatory phase, continued exposure desensitizes pituitary GnRH receptors and suppresses gonadotropin secretion.

PubChem CID 50225; C60H86N16O13; 1239.4 Da.

Regulatory label facts

United Kingdom national authorization (Suprecur); not FDA-approved and not an EMA centralized authorization.

The dose below reproduces a regulator-approved label; it is not a treatment recommendation.

Safety boundary

Use can initially worsen hormone-driven symptoms and later cause hypoestrogenic or hypoandrogenic effects, bone loss and mood or metabolic effects. The exact protocol depends on indication and product.

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

References

  1. 1.
    Buserelin — Primary regulatory source source
  2. 2.
    Buserelin — PubChem compound record source
  3. 3.
    Buserelin — Human study source

Frequently asked questions

What is Buserelin?
A GnRH agonist authorized nationally in the United Kingdom for specialist fertility protocols; it is not FDA-approved or centrally authorized by EMA.
Is Buserelin approved as a medicine, and where?
Buserelin is approved in some countries but not by the US FDA or the European Medicines Agency (EMA). Specifically: United Kingdom national authorization (Suprecur); not FDA-approved and not an EMA centralized authorization.
What is Buserelin studied for?
Buserelin is most often discussed in the context of approved peptide medicines — verification pilot. Being studied for an area does not mean it is proven or approved for it.
Does Buserelin have human clinical trials?
Yes. Buserelin has been studied in human clinical trials and is an approved medicine in at least some regions.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Buserelin is an approved medicine within the stated approval scope (United Kingdom national authorization (Suprecur); not FDA-approved and not an EMA centralized authorization) and must only be used under medical supervision; research-grade or unprescribed material is not a lawful substitute. Consult a qualified healthcare professional before making health decisions.

Related in Reproductive & Hormonal